the United States, it is standard treatment for patients with high-risk neuroblastoma (NBL) to receive the drugs carboplatin, etoposide and melphalan (CEM) as the preparative regimen in Consolidation therapy prior to Autologous Stem Cell Transplant (ASCT). BuMel Consolidation therapy has recently been studied in patients with high-risk NBL in some European countries. The findings from those studies indicate that the use of BuMel prior to ASCT may be linked to an increase in the survival rate for patients when compared to CEM. Those studies also indicate that the chance of the disease coming back (a relapse) may be lower among the patients who received BuMel Consolidation therapy. In North America the BuMel combination is considered experimental. In this study, researchers want to find out if a combination of busulfan and melphalan (BuMel) can be given as Consolidation therapy prior to ASCT for subjects with newly diagnosed high-risk NBL. The main goal of this study is to find out what effects, good and/or bad, a BuMel preparative regimen given before ASCT has on people with newly diagnosed high-risk NBL.
This study is for subjects with adenocarcinoma of the pancreas. The purpose of this research study is to determine the safety and effectiveness of Folfirinox and radiation therapy as treatment for adenocarcinoma (cancer) of the pancreas before surgery. Screening tests will be done to determine if subjects are eligible for participation in this study. If subjects are eligible to participate and agree to participate they will begin chemotherapy. After 3 cycles of chemotherapy, subjects will begin chemoradiation. Within 4 to 8 weeks of completing radiation therapy, subjects will have surgery. There will also be post-treatment and follow-up evaluations. Subjects will be followed for every 3 months for 3 years after their initial registration.
This is a study for subjects with glioblastoma brain tumors which have not received treatment other than surgery or biopsy. The purpose of this study is to find out what effects (good and bad) radiation therapy combined with temozolomide and RAD001 (everolimus) have on brain tumors. Before subjects begin study treatment screening procedures will be conducted to ensure subjects are eligible to participate. Subjects will be “randomized” into one of two study groups. Group 1 will receive radiation treatment with temozolomide. Group 2 will receive radiation treatment, temozolomide and RAD001. Subjects will receive treatment for 6 weeks. Subjects will return to clinic for a follow up exam 28 days later. Subjects will then take temozolomide and RAD001 for up to 12 months. They will then be asked to return for follow up exams every 3 months for the first year after treatment, every 4 months for the next year and every 6 months thereafter.
There is no current standard treatment for recurrent/refractory
medulloblastoma/PNET. The combination of the drugs temozolomide and
irinotecan has been used to treat adults and children with other types of cancer.
The combination has also been used in previous studies to treat a small number
of children with recurrent or refractory medulloblastoma/PNET as well as other
recurrent tumors, with encouraging results. This study uses the results of these
earlier studies, and looks at how well giving temozolomide and irinotecan daily
for 5 days every 28 days works when given to children and young adults with
recurrent or refractory medulloblastoma/PNET.
The purpose of this study is to develop a community-based strategy for increasing access to breast, prostate, and colon cancer among African Americans. We will also evaluate adoption of this program and determine if community-based navigation improves perceptions about cancer screening and has an impact on adherence.
The purpose of this study is to determine if integrated risk counseling is more effective than disease specific risk counseling on fruit and vegetable intake and physical activity among African American adults.
This study is for male patients that have received radiation for prostate cancer. This project is being done to study patterns of care for prostate cancer patients by establishing a national registry of adult male prostate cancer patients treated with radiation therapy in the United States. Information from about 500 patients across the country will be entered into the Registry in the first year. Over time, we expect to obtain records from about 3,500 patients being treated at up to 30 sites. A participant's diagnosis, treatment, and follow-up will not be affected by his participation in this project and will be consistent with standards of care at MUSC.
This study is for patients that have acute leukemia or myelodysplastic syndrome and are going to have a bone marrow, blood stem cell, or cord blood transplant to treat blood cancer. Stem cells are cells found in the bone marrow and blood and are able to grow into all the types of blood cells that the body needs.
The purpose of this research study is to see if adding the investigational drug, treosulfan, to the transplant conditioning regimen of fludarabine and total body irradiation (TBI) is safe and effective in subjects undergoing bone marrow, blood stem cell, or cord blood transplantation. Participants will be in the study for 1 year. After participants have recovered from any immediate transplant related complications, we will continue to collect information on how their marrow is functioning at routine follow-up visits.
Radiotherapy is a known treatment for many types of malignancies, but it is also a toxic treatment with variable side effects. Our goal is to develop biomarkers that predict radiotherapy efficacy and toxicity for various individual patients and malignancies. Biomarkers that verify radiosensitivity of particular tumors or response of normal tissues to radiotherapy would alleviate ineffective treatment strategies and unnecessary side effects. Preliminary data suggest that some plasma protiens are post translationally modified when animals are exposed to NOV-002 (drug that causes reactive oxygen species, similar to those reactive oxygen species caused by radiotherapy). Using a small amount of human blood, we intend to use immunoblot and proteomic analysis to identify possible biomarkers of response to radiotherapy. Two early leads have been protease inhibitors known as serpins (serine protease inhibitor and alpha-1-antitrypsin 1-6 precursor or Serpins a1 and a3). The activity of serpins may be attenuated by S-glutathionylation which may warant genotype analysis for glutathion-S-transferase-P. Furthermore, serpin S-glutathionylation induced by redox chemotherapeutics may have roles in the reversal of chemotherapy induced hematological suppression.